Oppenheimer Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Viracta Therapeutics (NASDAQ:VIRX) but lowers the price target from $13 to $11.
May 23, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer's analyst Hartaj Singh maintains an Outperform rating on Viracta Therapeutics but lowers the price target from $13 to $11.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100